Early Termination of Clinical Trials

"Early Termination of Clinical Trials" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Earlier than planned termination of clinical trials.

Descriptor ID	D057239
MeSH Number(s)	E05.581.500.400 N04.761.559.590.800.379 N05.715.360.575.575.800.379
Concept/Terms	Early Termination of Clinical Trials Early Termination of Clinical Trials

Below are MeSH descriptors whose meaning is more general than "Early Termination of Clinical Trials".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Methods [E05.581]
Research Design [E05.581.500]
Early Termination of Clinical Trials [E05.581.500.400]
Health Care [N]
Health Services Administration [N04]
Quality of Health Care [N04.761]
Outcome and Process Assessment (Health Care) [N04.761.559]
Outcome Assessment (Health Care) [N04.761.559.590]
Treatment Outcome [N04.761.559.590.800]
Early Termination of Clinical Trials [N04.761.559.590.800.379]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Outcome and Process Assessment (Health Care) [N05.715.360.575]
Outcome Assessment (Health Care) [N05.715.360.575.575]
Treatment Outcome [N05.715.360.575.575.800]
Early Termination of Clinical Trials [N05.715.360.575.575.800.379]

Below are MeSH descriptors whose meaning is related to "Early Termination of Clinical Trials".

Below are MeSH descriptors whose meaning is more specific than "Early Termination of Clinical Trials".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Early Termination of Clinical Trials" by people in this website by year, and whether "Early Termination of Clinical Trials" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2011 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	0	1	1
2011	2	0	2
2012	0	1	1
2013	0	1	1
2014	0	2	2
2017	0	1	1
2020	0	1	1

Below are the most recent publications written about "Early Termination of Clinical Trials" by people in Profiles.

Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, Gillmore J, Garg P, Vaishnaw AK, Harrop J, Powell C, Karsten V, Zhang X, Sweetser MT, Vest J, Hawkins PN. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.

View in: PubMed
Dungan K, Craven TE, Soe K, Wright JT, Basile J, Haley WE, Kressin NR, Rani U, Tamariz L, Whittle J, Wiggers A, Osei K. Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes Obes Metab. 2018 03; 20(3):629-637.

View in: PubMed
Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.

View in: PubMed
Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL, Jolly SS, Jacobs A, Newby LK, Gibson CM, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug; 7(8):857-67.

View in: PubMed
Connor JT, Elm JJ, Broglio KR. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S130-7.

View in: PubMed
Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7.

View in: PubMed
Abboud MR, Yim E, Musallam KM, Adams RJ. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011 Jul 28; 118(4):894-8.

View in: PubMed
Li JS, Colan SD, Sleeper LA, Newburger JW, Pemberton VL, Atz AM, Cohen MS, Golding F, Klein GL, Lacro RV, Radojewski E, Richmond ME, Minich LL. Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J. 2011 Feb; 161(2):233-40.

View in: PubMed
Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):124-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals